title: MAP3K3 overexpression is associated with poor survival in ovarian carcinoma.
abstract: Mitogen-activated protein kinase kinase kinase 3 (MAP3K3) is ubiquitously expressed in numerous tissues and is activated by various extracellular stimuli to regulate processes, such as cell proliferation and differentiation. Recent studies have identified potentially pathologic conditions of MAP3K3 as an oncogene that promotes tumor progression and metastasis in a number of malignancies. However, the clinical significance of MAP3K3 expression in ovarian carcinoma (OC) remains unclear. In this study, the correlation between MAP3K3 expression and OC prognosis was assessed by immunohistochemistry. MAP3K3 overexpression was observed in 59.1% (55/93) of OCs and was significantly associated with histological type and grade, chemotherapy response, and challenge model (P < .05, respectively). MAP3K3 overexpression was also used as an independent prognostic marker for decreased disease-free survival and overall survival. In OC cell lines, MAP3K3 expression was evaluated by Western blot analysis, quantitative real-time polymerase chain reaction, and immunofluorescence. High MAP3K3 expression is significantly detected in SKOV3, C13*, and A2780 cells. All these findings suggested that MAP3K3 overexpression is an independent poor prognostic indicator of OC and can be a clinically effective biomarker of OC.
authors.affiliation: Tongji Hospital Cancer Center, Tongji Medical College, Huazhong University of Science and Technology, Hubei, 430000, China; Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Jia
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Yuling
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Tao
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Pang
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Ren
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Weihua
authors.initials: W
authors.lastname: Liang
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Jinfang
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Department of Gynecology and Obstetrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Hubei, 430000, China; Department of Gynecology and Obstetrics, The First Affiliated Hospital of Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Cheng
authors.affiliation: Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China.
authors.forename: Wen Jie
authors.initials: WJ
authors.lastname: Zhang
authors.affiliation: Tongji Hospital Cancer Center, Tongji Medical College, Huazhong University of Science and Technology, Hubei, 430000, China.
authors.forename: Xianglin
authors.initials: X
authors.lastname: Yuan
authors.affiliation: Tongji Hospital Cancer Center, Tongji Medical College, Huazhong University of Science and Technology, Hubei, 430000, China; Department of Pathology, Shihezi University School of Medicine, Xinjiang, 832002, China; Department of Pathology, Beijing ChaoYang Hospital, Beijing, 100020, China. Electronic address: lifeng7855@126.com.
authors.forename: Feng
authors.initials: F
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002277:Carcinoma / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D048748:MAP Kinase Kinase Kinase 3 / Q000378:metabolism*; D008875:Middle Aged; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016016:Proportional Hazards Models; D013997:Time Factors; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D048748:MAP Kinase Kinase Kinase 3; C482625:MAP3K3 protein, human
keywords: Biomarker; MAP3K3; Oncogene; Ovarian carcinoma; Prognosis